Clinical Commander

Back to dossier
ob.amniotic-fluid-embolism.v1PRODUCTION
ob.amniotic-fluid-embolism.v1

Amniotic Fluid Embolism (AFE)

obstetricsacuteadultpregnancy
Hard-required inputs
0 / 15
Care setting:

Encounter flow

12/12 authored

Canonical 12-phase frame with authored status for this dossier.

Current phase

Frame

Detailed

Catastrophic obstetric emergency — anaphylactoid syndrome of pregnancy with sudden cardiopulmonary collapse + hypoxia + DIC during labor, delivery, or within 30 min postpartum. Clark 2016 case definition (PMID 27372270) requires ALL FOUR criteria: (1) sudden cardiorespiratory arrest OR hypotension with hypoxia, (2) DIC after cardiovascular event but before large-volume hemorrhage, (3) onset during labor or within 30 min postpartum, (4) no fever and no alternative explanation. Biphasic hemodynamic pattern: phase 1 acute pulm HTN + RV failure ± arrest (minutes), phase 2 LV failure + pulmonary edema + DIC + hemorrhage. Treatment is parallel resuscitation + emergent delivery + DIC management; no specific test exists — diagnosis is clinical.

Inputs
1
Actions
0
Advance rule
Set
Advance when

GA cohort tagged; phase 1 vs phase 2 hemodynamic pattern recognised if possible (often retrospective)

Patient inputs (23)

Fever ≥ 38.0°C / 100.4°F EXCLUDES AFE per Clark 2016 criterion 4 (favors sepsis ddx); critical differential anchor

Category III FHR / bradycardia / absent FHR drives emergent delivery decision (perimortem cesarean if maternal arrest)

Clark 2016 criterion 3 — onset during labor, delivery, or within 30 min postpartum; temporal association is essential to the diagnosis

GA ≥ 20–24 wk drives perimortem cesarean indication if maternal arrest; preterm < 24 wk changes neonatal viability calculus

Platelet count for DIC surveillance (Clark 2016 criterion 2); baseline Hgb for hemorrhagic-shock trajectory

DIC surveillance — fibrinogen < 200 mg/dL in pregnancy is profoundly low (baseline 350-650); prolonged PT/aPTT; ISTH Pregnancy DIC score; routes to cryoprecipitate + FFP + platelets

Massive transfusion protocol activation; uncrossmatched O-negative if life-threatening + type-pending; crossmatched once available

Renal function trajectory (hypoperfusion-AKI), electrolytes (K+ in massive transfusion), liver function (DIC + congestion ddx with HELLP)

Shock marker; rising lactate drives MCS + ECMO consideration in refractory AFE

Hypoxemia + acidosis pattern; AaDO2 + PaO2/FiO2 ratio guide ventilation + ECMO threshold

Phase 1 AFE — dilated RV + flattened septum + acute pulm HTN pattern; differentiates from LV-predominant cardiomyopathy + acute coronary syndrome; tracks recovery trajectory

Sudden hypotension SBP < 90 OR MAP < 65 is a Clark 2016 criterion-1 component; defines hemodynamic instability driving emergent resuscitation

Bradycardia / asystole / tachyarrhythmia drives ACLS algorithm; A-OK (atropine first) may be reasonable in bradycardic AFE pattern

Tachypnea / apnea drives airway management + mechanical ventilation; respiratory failure in AFE is profound

SpO2 < 90 with cyanosis or dyspnea is a Clark 2016 criterion-1 component (hypoxia); drives FiO2 1.0 + mechanical ventilation + iNO consideration

PE differential — markedly elevated in both AFE and PE; not diagnostic but helps rule-in thromboembolic process when CT-PA unavailable

PE differential — CT-PA if patient stable enough + AFE/PE ambiguity persists; NOT prerequisite for treatment; do NOT delay resuscitation for imaging

Recent membrane rupture, amnioinfusion, D&C, or uterine instrumentation are precipitating events; informs temporal-association diagnostic anchor

Helps differentiate anaphylaxis from AFE; pre-event allergen exposure favors anaphylaxis; lack of trigger + temporal association with delivery favors AFE

PE differential — recent immobility, prior VTE, thrombophilia raise PE pretest probability; CT-PA if AFE/PE ambiguity persists after initial resuscitation

Eclamptic seizure ddx — pre-eclampsia history + HTN + seizure-like activity favors eclampsia (magnesium responsive); AFE typically lacks this profile

Rule out concurrent ACS / cardiomyopathy; elevated in AFE due to RV strain + low CO; serial trajectory marker

Pulmonary edema pattern (phase 2 AFE); pneumothorax / hemothorax differential during resuscitation; lung ultrasound B-lines pattern

* = hard-required. Engine cannot meaningfully run until these are filled.

Severity triggers (9)

9 need judgement
  • informationallife_threateningafe_at_presentation_emergent_resuscitation
    Amniotic fluid embolism at presentation — sudden cardiopulmonary collapse + hypoxia ± DIC during labor / delivery / immediate postpartum within 30 min (Clark 2016 criteria PMID 27372270) — life-threatening; immediate ATLS + ACLS framework + left-uterine displacement + multidisciplinary team activation (OB + anesthesia + critical care + cardiothoracic / ECMO + neonatology + hematology); do NOT delay treatment for confirmatory imaging — diagnosis is clinical
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationallife_threateningperimortem_cesarean_within_4_5_min
    Maternal cardiac arrest in 3rd trimester (GA ≥ 20–24 wk by fundal height) with no immediate response to ACLS — life-threatening; perimortem cesarean within 4–5 min improves both maternal venous return + fetal outcomes (AHA 2015 maternal arrest PMID 26443610; AHA 2024 update); do NOT delay for confirmatory imaging or fetal viability assessment
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationallife_threateningafe_with_dic_hemorrhage
    AFE phase 2 — overt DIC + active obstetric hemorrhage (uterine atony, surgical-site bleeding, oozing IV sites, mucosal bleeding) — life-threatening; massive transfusion protocol 1:1:1 PRBC:FFP:platelets + cryoprecipitate 10 units if fibrinogen < 200 + tranexamic acid 1 g IV within 3 h + factor VIIa or PCC per hematology consult; surgical hemostasis if uncontrolled (uterotonics + tamponade + B-Lynch + uterine artery ligation + hysterectomy)
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationallife_threateningpulm_htn_with_rv_failure_afe_phase_1
    AFE phase 1 — acute pulmonary HTN + right ventricular failure pattern on echocardiogram (dilated RV + flattened septum) + profound hypoxia — life-threatening; inhaled nitric oxide 20–40 ppm first-line + sildenafil 20–40 mg PO/NG q4–8h + milrinone 0.25–0.5 mcg/kg/min IV + epoprostenol inhaled or IV; norepinephrine for systemic hypotension + dobutamine for low CO; refractory → VA-ECMO consideration
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationallife_threateninglv_failure_afe_phase_2
    AFE phase 2 — LV failure + pulmonary edema + cardiogenic shock (typically after phase 1 RV failure resolves but LV dysfunction emerges) — life-threatening; inotropes (dobutamine or milrinone) + cautious diuresis + vasoactive support; avoid fluid overload; mechanical ventilation with optimised PEEP; ECMO consideration if refractory
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationallife_threateningafe_refractory_va_ecmo
    Refractory AFE cardiopulmonary collapse despite max NE + AVP + milrinone + iNO + epoprostenol + MTP — life-threatening; VA-ECMO consideration as bridge to recovery; multidisciplinary decision (critical care + cardiothoracic + OB + ethics); mortality on ECMO still ~ 50% but recovery is genuinely achievable in select cases (ELSO 2020 obstetric ECMO registry + Sharma 2017 PMID 25248040)
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalsevereafe_survivor_hypoxic_ischemic_injury
    AFE survivor with hypoxic-ischemic encephalopathy (HIE) — post-ROSC persistent coma, focal neurologic deficits, or cognitive impairment — severe; targeted temperature management 32–36°C × 24 h if comatose immediately post-ROSC (AHA 2020); neurology + neuropsychology consultation + multimodal prognostication at 72 h post-rewarming; rehabilitation services (PT, OT, speech) as recovery progresses; family + ethics support
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalseveredifferential_from_pe_septic_anaphylaxis_eclampsia
    Broad differential evaluation in parallel with resuscitation — pulmonary embolism (CT-PA + d-dimer + echo RV strain pattern), septic shock (fever ≥ 38.0°C excludes AFE per Clark 2016 criterion 4; blood cultures + procalcitonin), anaphylaxis (allergen trigger + skin findings + tryptase + epinephrine response), eclampsia (HTN + seizure + pre-eclampsia history + magnesium response), peripartum cardiomyopathy with cardiogenic shock, acute MI / SCAD, tension pneumothorax, total spinal anesthetic, uterine rupture, placental abruption with DIC — severe; do NOT delay resuscitation for confirmatory imaging — treat empirically based on temporal association + DIC + cardiopulmonary collapse pattern; CT-PA only if patient stable enough + AFE / PE ambiguity persists
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalmoderateafe_in_subsequent_pregnancy
    Subsequent pregnancy after prior AFE — moderate (not severe); recurrence is rare (~ 1% per AFE Registry data); NOT a contraindication to pregnancy but high-risk MFM coordination + delivery at tertiary center with on-call critical care + ECMO capability recommended; counsel family + psychosocial support; survivor support groups (AFE Foundation)
    Trigger could not be auto-evaluated — needs clinician judgement.

Workflow calculators

Run this disease's risk and dosing calculators inline.

RISK_STRATIFICATIONoptionalDrives screening
Loading…

Recommended regimen

AFE acute resuscitation — ATLS/ACLS + perimortem cesarean + pulmonary vasodilators + vasoactive support + massive transfusion + ECMO consideration (Clark 2016 PMID 27372270 + SMFM 9 Pacheco 2016 PMID 26987420 + AHA 2015 maternal arrest PMID 26443610 + ELSO 2020 obstetric ECMO + ESC Pregnancy 2018 PMID 30165544)
axis: amniotic_fluid_embolism_acute_resuscitationstep acls_with_perimortem_cesarean - ACLS + perimortem cesarean within 4–5 min if maternal arrest ≥ 20–24 wk (AHA 2015 PMID 26443610; AHA 2024 update)
Selected step "ACLS + perimortem cesarean within 4–5 min if maternal arrest ≥ 20–24 wk (AHA 2015 PMID 26443610; AHA 2024 update)" — Maternal cardiac arrest + GA ≥ 20–24 wk by fundal height + arrest not promptly responsive to ACLS + left-uterine displacement
  • epinephrine
    first line
    alpha_beta_agonist_vasopressor
    1 mg IV/IO q3–5 min during cardiac arrest • IV/IO • q3–5 min during arrest
    triggers: maternal_cardiac_arrest
    AHA 2020 ACLS standard; left-uterine displacement maintained throughout; perimortem cesarean if no ROSC in 4–5 min
    rxcui 3992
  • amiodarone
    first line
    class_iii_antiarrhythmic
    300 mg IV/IO bolus for VF/pulseless VT; 150 mg IV/IO repeat if refractory • IV/IO • bolus, may repeat × 1
    triggers: shockable_rhythm_vf_or_pulseless_vt
    AHA 2020 ACLS — shockable rhythm management
    rxcui 703

outpatient playbook — drug actions (5)

  1. 1. iron repletion if postpartum anemia
    rxcui 24947
    Ferrous sulfate 325 mg PO TID OR IV iron if severe anemia (Hgb < 8) or non-tolerant • PO/IV • TID PO or per infusion protocol
    trigger: Postpartum Hgb < 11 g/dL
    Restore iron stores; reduce fatigue + improve recovery
  2. 2. antidepressant for postpartum depression
    rxcui 36437
    Sertraline 25–50 mg PO daily; titrate to therapeutic dose per psychiatry • PO • daily
    trigger: EPDS ≥ 10 OR suicidal ideation OR symptoms persistent ≥ 2 wk
    ACOG CO 757 2018 / WHO MEC — sertraline preferred SSRI in lactation; lactation-compatible
  3. 3. PTSD-focused therapy ± pharmacotherapy
    CBT or EMDR; sertraline or paroxetine if pharmacotherapy indicated • PO if pharmacotherapy • per agent
    trigger: PCL-5 elevated OR persistent intrusive symptoms
    APA + VA/DoD PTSD guidelines; high risk after catastrophic peripartum event
  4. 4. contraception
    Per ACOG MEC + patient preference (LARC, COC, POP, DMPA, etc.) • PO/IM/implant/IUD • per agent
    trigger: Patient request + medical eligibility
    Avoid short interpregnancy interval (< 18 mo associated with worse outcomes); ACOG MEC
  5. 5. influenza + COVID + Tdap vaccines per ACIP
    Per ACIP • IM • per schedule
    trigger: Postpartum
    Standard ACIP recommendations

Auto-drafted A&P note

outpatient

Subjective

- Possible entry pathways: Sudden cardiovascular collapse (SBP < 90 / MAP < 65 / cardiac arrest) + hypoxia (SpO2 < 90 / cyanosis / dyspnea) during labor, delivery, or within 30 min postpartum — gateway clinical feature (Clark 2016 PMID 27372270); Sudden onset severe dyspnea + altered mental status / agitation / seizure-like activity in labor or immediate postpartum — early prodrome (Clark 2016 PMID 27372270; SMFM 9 Pacheco 2016 PMID 26987420); Sudden onset DIC features (fibrinogen < 200, platelets < 100, prolonged PT/aPTT, oozing IV sites, surgical-site / uterine bleeding) in immediate temporal association with delivery — Clark 2016 criterion 2 (PMID 27372270).

Objective

- No vitals, labs, or imaging entered for this encounter.

Assessment

**Amniotic Fluid Embolism (AFE)** (ob.amniotic-fluid-embolism.v1).
Phenotype framing: Pulmonary embolism (CT-PA + d-dimer + echo RV strain — overlapping; DIC pattern of AFE differentiates), anaphylaxis (allergen trigger + skin findings + tryptase + epinephrine response — overlapping anaphylactoid pattern), eclampsia (HTN + seizure + pre-eclampsia history + magnesium response), septic shock (fever + chorio overlap — Clark criterion 4 excludes AFE), peripartum cardiomyopathy with CS (LV-predominant + earlier subacute presentation), acute MI / SCAD (ECG + troponin pattern; coronary angiography), tension pneumothorax (asymmetric breath sounds + tracheal shift), total spinal anesthetic (recent neuraxial procedure + bilateral motor block), uterine rupture (prior cesarean + abdominal pain + fetal station change), placental abruption with DIC (painful bleeding + uterine tenderness + retroplacental clot if visible).
Scope: Catastrophic obstetric emergency — anaphylactoid syndrome of pregnancy with sudden cardiopulmonary collapse + hypoxia + DIC during labor, delivery, or within 30 min postpartum. Clark 2016 case definition (PMID 27372270) requires ALL FOUR criteria: (1) sudden cardiorespiratory arrest OR hypotension with hypoxia, (2) DIC after cardiovascular event but before large-volume hemorrhage, (3) onset during labor or within 30 min postpartum, (4) no fever and no alternative explanation. Biphasic hemodynamic pattern: phase 1 acute pulm HTN + RV failure ± arrest (minutes), phase 2 LV failure + pulmonary edema + DIC + hemorrhage. Treatment is parallel resuscitation + emergent delivery + DIC management; no specific test exists — diagnosis is clinical.

No severity triggers fired against current inputs.

Plan

Regimen axis: **AFE acute resuscitation — ATLS/ACLS + perimortem cesarean + pulmonary vasodilators + vasoactive support + massive transfusion + ECMO consideration (Clark 2016 PMID 27372270 + SMFM 9 Pacheco 2016 PMID 26987420 + AHA 2015 maternal arrest PMID 26443610 + ELSO 2020 obstetric ECMO + ESC Pregnancy 2018 PMID 30165544)** — step "ACLS + perimortem cesarean within 4–5 min if maternal arrest ≥ 20–24 wk (AHA 2015 PMID 26443610; AHA 2024 update)".
1. epinephrine 1 mg IV/IO q3–5 min during cardiac arrest IV/IO q3–5 min during arrest (alpha_beta_agonist_vasopressor, first line) — AHA 2020 ACLS standard; left-uterine displacement maintained throughout; perimortem cesarean if no ROSC in 4–5 min
2. amiodarone 300 mg IV/IO bolus for VF/pulseless VT; 150 mg IV/IO repeat if refractory IV/IO bolus, may repeat × 1 (class_iii_antiarrhythmic, first line) — AHA 2020 ACLS — shockable rhythm management

Setting playbook (outpatient) — 6-wk postpartum visit + AFE-specific anticipatory guidance — survivors at risk for hypoxic-ischemic encephalopathy + peripartum PTSD + postpartum depression; subsequent-pregnancy counseling (recurrence rare ~ 1%; not a contraindication but high-risk MFM coordination); newborn high-risk peds 24–48 h post-discharge + developmental tracking
3. iron repletion if postpartum anemia Ferrous sulfate 325 mg PO TID OR IV iron if severe anemia (Hgb < 8) or non-tolerant PO/IV TID PO or per infusion protocol — Postpartum Hgb < 11 g/dL (Restore iron stores; reduce fatigue + improve recovery)
4. antidepressant for postpartum depression Sertraline 25–50 mg PO daily; titrate to therapeutic dose per psychiatry PO daily — EPDS ≥ 10 OR suicidal ideation OR symptoms persistent ≥ 2 wk (ACOG CO 757 2018 / WHO MEC — sertraline preferred SSRI in lactation; lactation-compatible)
5. PTSD-focused therapy ± pharmacotherapy CBT or EMDR; sertraline or paroxetine if pharmacotherapy indicated PO if pharmacotherapy per agent — PCL-5 elevated OR persistent intrusive symptoms (APA + VA/DoD PTSD guidelines; high risk after catastrophic peripartum event)
6. contraception Per ACOG MEC + patient preference (LARC, COC, POP, DMPA, etc.) PO/IM/implant/IUD per agent — Patient request + medical eligibility (Avoid short interpregnancy interval (< 18 mo associated with worse outcomes); ACOG MEC)
7. influenza + COVID + Tdap vaccines per ACIP Per ACIP IM per schedule — Postpartum (Standard ACIP recommendations)

Non-pharmacologic actions:
- Neurology + neuropsychology evaluation if HIE
- Rehabilitation services (PT, OT, speech) for HIE sequelae
- Mental health counseling / therapy if EPDS ≥ 10 or PCL-5 elevated
- Lactation continued support if breastfeeding (LactMed lookup for all medications)
- Subsequent-pregnancy MFM preconception consultation + tertiary center delivery recommendation if next pregnancy contemplated
- Pediatric follow-up coordination for high-risk newborn — 24–48 h post-discharge peds visit, then 1 wk + 1 mo developmental + immunization tracking
- Family + survivor support — AFE Foundation + peer support groups
- Cardiothoracic / pulmonology follow-up if RV recovery incomplete
- Hematology follow-up if persistent coagulopathy

AVOID / contraindication checks:
- NSAIDs caution during active DIC and hemorrhage (ketorolac in A OK regimen — weigh empiric benefit against bleeding risk)
- Do not delay perimortem cesarean for imaging or fetal viability assessment if arrest and ge 20 to 24 wk (AHA 2015 PMID 26443610)
- Left uterine displacement mandatory during ACLS in pregnancy if undelivered (AHA 2015)
- Methylergonovine contraindicated in PE or PHTN or pre eclampsia overlap (ACOG PB 183 2017)
- Carboprost contraindicated in asthma or acute pulm edema or severe pulm HTN (ACOG PB 183 2017)
- Methylene blue CI in severe G6PD deficiency (use cautiously)
- Inhaled NO monitor methemoglobinemia q4 to 8h (ESC Pregnancy 2018)
- Sildenafil systemic hypotension risk caution if MAP not yet restored (ESC Pregnancy 2018)
- AFE clinical diagnosis no specific test do not defer treatment pending confirmation (Clark 2016 PMID 27372270)

Monitoring

Regimen monitoring:
- Continuous MAP + ECG + SpO2 + capnography + arterial line + central venous catheter
- ABG q1–4 h during instability
- Lactate q2–4 h until normalised
- Serial coag panel q1–2 h while active bleeding; q4–6 h stabilising
- Fibrinogen target ≥ 200 mg/dL with cryoprecipitate replacement
- Platelet target > 50K intrapartum; > 100K with active hemorrhage
- Echocardiography q12–24 h to track RV recovery + ECMO weaning readiness
- Daily SOFA + cultures + antimicrobial review
- CAM-ICU + RASS daily once sedation lightened
- Targeted temperature management 32–36°C × 24 h if comatose post-ROSC
- Methemoglobinemia surveillance q4–8 h if on inhaled nitric oxide
- Fetal monitoring continuous if not yet delivered

Setting (outpatient) monitoring:
- 6-wk postpartum visit; additional visit at 1–2 wk if cesarean wound concern
- Newborn outpatient peds at 24–48 h then 1 wk then 1 mo
- Maternal mental health re-screen at 6 wk + 3 mo + 6 mo (PCL-5 + EPDS)
- Neurology / neuropsychology re-assessment q3–6 mo for first year if HIE
- Future-pregnancy preconception visit when contemplated

Follow-up plan: 6-wk postpartum visit + AFE-specific anticipatory guidance. Survivors at risk for hypoxic-ischemic encephalopathy → neurology + neuropsychology evaluation; rehabilitation services as needed. Mental health screen — high risk for peripartum PTSD (PCL-5) + postpartum depression (EPDS) given catastrophic peripartum event. Subsequent-pregnancy counseling: recurrence rare (~ 1%; AFE Registry data); NOT a contraindication to pregnancy but high-risk MFM coordination + delivery at tertiary center with on-call critical care + ECMO capability. Newborn outpatient peds 24–48 h post-discharge + developmental tracking for first year (high CP / BPD risk if hypoxic-ischemic exposure). Cardiothoracic / pulmonology follow-up if RV recovery incomplete. Hematology follow-up if persistent coagulopathy. Family + psychosocial support; survivor support groups (AFE Foundation).
- Close-out criterion: Postpartum visit complete; neurology / neuropsych / rehab assessment if HIE; mental health support engaged; subsequent-pregnancy counseling delivered; newborn developmental tracking initiated; family support arranged

Monitoring phase: Continuous MAP + ECG + SpO2 + capnography + arterial line + central venous catheter once on vasopressors. ABG q1–4 h during instability. Lactate q2–4 h until normalised. Serial coag panel q1–2 h while active bleeding then q4–6 h stabilising; fibrinogen target ≥ 200 with cryoprecipitate replacement; platelet target > 50K intrapartum > 100K with active hemorrhage. Echocardiography q12–24 h to track RV recovery + ECMO weaning readiness. Daily SOFA + cultures. Fetal monitoring continuous if not yet delivered. CAM-ICU once sedation lightened. Targeted temperature management 32–36°C × 24 h if comatose post-ROSC.

Disposition

Current setting: outpatient — 6-wk postpartum visit + AFE-specific anticipatory guidance — survivors at risk for hypoxic-ischemic encephalopathy + peripartum PTSD + postpartum depression; subsequent-pregnancy counseling (recurrence rare ~ 1%; not a contraindication but high-risk MFM coordination); newborn high-risk peds 24–48 h post-discharge + developmental tracking

Disposition criteria:
- Resolution: 6-wk postpartum visit complete, mental health stable, contraception in place, immunizations up to date, neurology / cardiothoracic / hematology follow-ups arranged, newborn developmental tracking ongoing → discharge from AFE-specific surveillance back to routine primary care + MFM referral for next pregnancy

Escalation triggers (move to higher acuity):
- New mental health crisis (PHQ-9 ≥ 15 or suicidal ideation or PTSD impairment) → urgent mental health referral
- Newborn high-risk features (persistent feeding issues, neurodevelopmental concerns) → urgent peds visit
- New cardiac symptoms (dyspnea, edema, palpitations) → cardiology urgent visit
- New bleeding / bruising / coagulopathy → hematology urgent visit
- Persistent cognitive / neurologic deficits → neurology + neuropsychology + rehabilitation escalation

Earlier-Return Triggers

Return-precaution thresholds (watch for):
- [LIFE_THREATENING] Amniotic fluid embolism at presentation — sudden cardiopulmonary collapse + hypoxia ± DIC during labor / delivery / immediate postpartum within 30 min (Clark 2016 criteria PMID 27372270) — life-threatening; immediate ATLS + ACLS framework + left-uterine displacement + multidisciplinary team activation (OB + anesthesia + critical care + cardiothoracic / ECMO + neonatology + hematology); do NOT delay treatment for confirmatory imaging — diagnosis is clinical
- [LIFE_THREATENING] Maternal cardiac arrest in 3rd trimester (GA ≥ 20–24 wk by fundal height) with no immediate response to ACLS — life-threatening; perimortem cesarean within 4–5 min improves both maternal venous return + fetal outcomes (AHA 2015 maternal arrest PMID 26443610; AHA 2024 update); do NOT delay for confirmatory imaging or fetal viability assessment
- [LIFE_THREATENING] AFE phase 2 — overt DIC + active obstetric hemorrhage (uterine atony, surgical-site bleeding, oozing IV sites, mucosal bleeding) — life-threatening; massive transfusion protocol 1:1:1 PRBC:FFP:platelets + cryoprecipitate 10 units if fibrinogen < 200 + tranexamic acid 1 g IV within 3 h + factor VIIa or PCC per hematology consult; surgical hemostasis if uncontrolled (uterotonics + tamponade + B-Lynch + uterine artery ligation + hysterectomy)

Citations

- Clark SL et al — Proposed diagnostic criteria for the case definition of amniotic fluid embolism in research studies (Am J Obstet Gynecol 2016 PMID 27372270) — canonical clinical diagnostic criteria anchor + SMFM Consult Series 9 — Amniotic fluid embolism: diagnosis and management (Pacheco LD, Saade G, Hankins GDV; Am J Obstet Gynecol 2016 PMID 26987420) + Conde-Agudelo A, Romero R (Am J Obstet Gynecol 2009 PMID 19879393) — epidemiology + outcomes anchor + Knight M et al, UKOSS (Obstet Gynecol 2010 PMID 20410762) — UK national surveillance + Clark SL (Am J Obstet Gynecol 1995 PMID 7726251) — original anaphylactoid hypothesis + AHA 2015 maternal arrest (Jeejeebhoy FM et al, Circulation 2015 PMID 26443610; AHA 2024 update) — perimortem cesarean within 4–5 min + ELSO 2020 obstetric ECMO registry + Sharma NS et al (ASAIO J 2015 PMID 25248040) — ECMO in pregnancy/postpartum series (incl AFE) + Rezai S et al (Case Rep Obstet Gynecol 2017 PMID 29430313) — A-OK proposed empiric combination + Pacheco LD et al (Am J Obstet Gynecol 2016 PMID 26348379) — massive transfusion protocols in obstetrics + WOMAN trial Shakur 2017 (PMID 28456509) — TXA in PPH + ESC Pregnancy 2018 (Regitz-Zagrosek V et al PMID 30165544) — pulmonary vasodilator + RV support framework [PMID:27372270](https://pubmed.ncbi.nlm.nih.gov/27372270/)
- Cited evidence (PMID 26987420) [PMID:26987420](https://pubmed.ncbi.nlm.nih.gov/26987420/)
- Cited evidence (PMID 19879393) [PMID:19879393](https://pubmed.ncbi.nlm.nih.gov/19879393/)
- Cited evidence (PMID 20410762) [PMID:20410762](https://pubmed.ncbi.nlm.nih.gov/20410762/)
- Cited evidence (PMID 7726251) [PMID:7726251](https://pubmed.ncbi.nlm.nih.gov/7726251/)

Last reconciled with current guidelines: 2026-05-15.
References
  • Clark SL et al — Proposed diagnostic criteria for the case definition of amniotic fluid embolism in research studies (Am J Obstet Gynecol 2016 PMID 27372270) — canonical clinical diagnostic criteria anchor + SMFM Consult Series 9 — Amniotic fluid embolism: diagnosis and management (Pacheco LD, Saade G, Hankins GDV; Am J Obstet Gynecol 2016 PMID 26987420) + Conde-Agudelo A, Romero R (Am J Obstet Gynecol 2009 PMID 19879393) — epidemiology + outcomes anchor + Knight M et al, UKOSS (Obstet Gynecol 2010 PMID 20410762) — UK national surveillance + Clark SL (Am J Obstet Gynecol 1995 PMID 7726251) — original anaphylactoid hypothesis + AHA 2015 maternal arrest (Jeejeebhoy FM et al, Circulation 2015 PMID 26443610; AHA 2024 update) — perimortem cesarean within 4–5 min + ELSO 2020 obstetric ECMO registry + Sharma NS et al (ASAIO J 2015 PMID 25248040) — ECMO in pregnancy/postpartum series (incl AFE) + Rezai S et al (Case Rep Obstet Gynecol 2017 PMID 29430313) — A-OK proposed empiric combination + Pacheco LD et al (Am J Obstet Gynecol 2016 PMID 26348379) — massive transfusion protocols in obstetrics + WOMAN trial Shakur 2017 (PMID 28456509) — TXA in PPH + ESC Pregnancy 2018 (Regitz-Zagrosek V et al PMID 30165544) — pulmonary vasodilator + RV support framework — PMID:27372270
  • Cited evidence (PMID 26987420) — PMID:26987420
  • Cited evidence (PMID 19879393) — PMID:19879393
  • Cited evidence (PMID 20410762) — PMID:20410762
  • Cited evidence (PMID 7726251) — PMID:7726251